Antibiotic treatment outcomes in community-acquired pneumonia

Creative Commons License

ÇİLLİ A., SAYINER A., ÇELENK B., Sakar Coskun A., KILINÇ O., Hazar A., ...More

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.48, no.4, pp.730-736, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 48 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.3906/sag-1709-144
  • Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.730-736
  • Keywords: Pneumonia, beta-lactam, fluoroquinolone, macrolide, BETA-LACTAM MONOTHERAPY, ADULTS, RESISTANCE, MACROLIDES, MORTALITY, THERAPY, GUIDELINES, MANAGEMENT, PATHOGENS
  • Akdeniz University Affiliated: Yes

Abstract

Background/aim: The optimal empiric antibiotic regimen for patients with community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate the clinical cure rate, mortality, and length of stay among patients hospitalized with community-acquired pneumonia in nonintensive care unit (ICU) wards and treated with a beta-lactam, beta-lactam and macrolide combination, or a fluoroquinolone.